EQIPD consortium develops quality system to facilitate adherence to evidence-based research practices

The European Quality in Preclinical Data (EQIPD) consortium has announced the official finalisation of the EQIPD Innovative Medicines Initiative (IMI) project.

Over the course of four years the consortium has developed a state-of-the-art, lean and fit-for-purpose quality system to facilitate adherence to rigorous, evidence-based research practices in academic and industrial non-regulated non-clinical research .

To make the quality system widely available, the consortium has launched an online educational platform providing education and training in the principles and application of quality and rigour, and published recommendations for the internal validity in the design, conduct and analysis of biomedical experiments involving laboratory animals.

Professor Malcolm Macleod of the University of Edinburgh, co-ordinator of the EQIPD consortium, said: “The EQIPD partners worked very efficiently as a cohesive unit, even when challenged by unforeseen circumstances, such as the Covid pandemic. Via access to non-clinical data from industry we have been able to explore those variables in study design and data analysis that influence outcomes in preclinical neuroscience and safety studies conducted in industry, and to establish whether these are the same variables that influence outcomes in academic studies. The outcomes from this analysis and the recommendations of internal validity informed a series of animal experiments conducted by the consortium, and we were able to demonstrate the benefits of harmonisation across labs.”

To sustain the efforts of the consortium, EQIPD is in the process of founding the Guarantors of EQIPD society. Dr Thomas Steckler of Janssen Pharmaceutica, project leader of the EQIPD consortium, added: “The Guarantors of EQIPD consist of a group of the EQIPD project team members and will be responsible for the overall guidance and administration of academic and educational programmes, and the dissemination of the EQIPD vision. The guarantors will oversee the deployment of the EQIPD Quality System, working with by an independent globally acting partner organisation to provide the operational support and services required for day-to-day business management during the implementation and maintenance of the EQIPD Quality System at interested research units.”

The EQIPD quality system is freely available and can be accessed at or Research units interested in the quality system are encouraged to contact [email protected] for additional information.

The EQIPD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777364. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

European College of Neuropsychopharmacology (ECNP)

Content Source:

Gemma Wilson

Gemma is a journalism graduate with keen interest in covering business news – specifically startups. She has as a keen eye for technologies and has predicted quite a few successful startups over the last couple of years.

Related Articles